Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3643)	5/1/2001 9:30:46 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Clear evidence of a slowdown at the FDA for NME (new molecular entity) approvals: Approval Times (In Months) for NDAs and NMEs Approved Fiscal Years 1988-2000 (Updated 4/24/2001) fda.gov 2000 was still better than 1997, but clearly 1998 and 1999 are now "the good old days." These statistics are also interesting: Active Investigational New Drugs (INDs) at the Close of the Calendar Year - Calendar Years 1986-2000 (Updated 4/24/2001) fda.gov INDs Received Calendar Years 1986-2000 (Updated 4/24/2001) fda.gov So the rate of commercial IND's has been pretty constant, with a slight 1998 peak. Active IND's have been very steady, with a modest secular growth trend. Be interesting to know what % of the IND's have been from biotechs vs. from pharmas, and what % of the IND's are for NME's. About 40% of approvals are for NME's, but approval rates are bound to be higher for the non-NME's and NME's must also have substantially higher attrition. So at a rough guess NME IND's must be well over 50% of all IND's. Peter